Axa’s Cellectis CLLS Stock Holding History

Axa’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-166,068	Closed	-$2.77M	–	1323
2018 Q4	$2.77M	Hold	166,068	–	–	0.01%	755
2018 Q3	$4.69M	Hold	166,068	–	–	0.02%	695
2018 Q2	$4.7M	Buy	+166,068	New	+$4.94M	0.02%	673

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Axa's CLLS Position: Q1 2019 in Review

Axa sold out of Cellectis (CLLS) in Q1 2019, closing a stake of 166,068 shares — an estimated $2.77M sold.

Axa first reported a position in CLLS in Q2 2018 and held it in 3 quarters. The position peaked at $4.7M in Q2 2018. 63 funds tracked by Wall St. Rank hold CLLS as of Q1 2019.

Axa reported no remaining Cellectis position as of Q1 2019 after selling out during the quarter.
Axa sold 166,068 Cellectis shares in Q1 2019, an estimated $2.77M.
Axa first reported a position in Cellectis in Q2 2018 and held it in 3 quarters.
Axa's Cellectis position peaked at $4.7M in Q2 2018.
63 funds tracked by Wall St. Rank held Cellectis as of Q1 2019.

Based on Axa's 13F filing for Q1 2019, filed 14 May 2019.